PMID- 38457057
OWN - NLM
STAT- MEDLINE
DCOM- 20240311
LR  - 20240312
IS  - 0942-0940 (Electronic)
IS  - 0001-6268 (Print)
IS  - 0001-6268 (Linking)
VI  - 166
IP  - 1
DP  - 2024 Mar 8
TI  - Optimizing patient outcome in intracranial tumor surgery: a detailed prospective 
      study of adverse events and mortality reduction strategies in neurosurgery.
PG  - 126
LID - 10.1007/s00701-024-06008-y [doi]
LID - 126
AB  - INTRODUCTION: Brain tumor surgery represents a critical and high-risk area within 
      the field of neurosurgery. Our study aims to offer a comprehensive analysis of 
      adverse events (AEs) from a prospectively maintained database at a leading 
      neurosurgical tertiary center, with a specific focus on different types of tumor 
      entities. METHODS: From January 2022 to September 2023, our study focused on 
      adult patients, who underwent surgery for intracranial tumors. Each patient in 
      this demographic was thoroughly assessed for adverse events (AEs) by their 
      attending physicians at discharge. An AE was defined as any event occurring 
      within the first 30 days post-surgery. RESULTS: A total of 1173 patients with an 
      average age of 57.4 +/- 15.3 years underwent surgical procedures. The majority of 
      these surgeries were elective, accounting for 93.4% (1095 out of 1173), while 
      emergency surgeries constituted 13.9% (163 out of 1173). The incidence of 
      surgery-related AEs was relatively low at 12.7%. The most common surgical 
      indications were meningioma and glioma pathologies, representing 31.1% and 28.2% 
      of cases, respectively. Dural leaks occurred in 1.5% of the cases. Postoperative 
      hemorrhage was a significant complication, especially among glioma patients, with 
      ten experiencing postoperative hemorrhage and eight requiring revision surgery. 
      The overall mortality rate stood at 0.8%, corresponding to five patient deaths. 
      Causes of death included massive postoperative bleeding in one patient, pulmonary 
      embolism in two patients, and tumor progression in two others. CONCLUSIONS: 
      Surgical interventions for intracranial neoplasms are inherently associated with 
      a significant risk of adverse events. However, our study's findings reveal a 
      notably low mortality rate within our patient cohort. This suggests that thorough 
      documentation of AEs, coupled with proactive intervention strategies in 
      neurosurgical practices, can substantially enhance patient outcomes.
CI  - (c) 2024. The Author(s).
FAU - Lenga, Pavlina
AU  - Lenga P
AD  - Department of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 
      400, 69120, Heidelberg, Germany. pavlina.lenga@med.uni-heidelberg.de.
AD  - Medical Faculty of Heidelberg University, Heidelberg, Germany. 
      pavlina.lenga@med.uni-heidelberg.de.
FAU - Kleineidam, Helena
AU  - Kleineidam H
AD  - Department of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 
      400, 69120, Heidelberg, Germany.
AD  - Medical Faculty of Heidelberg University, Heidelberg, Germany.
FAU - Unterberg, Andreas
AU  - Unterberg A
AD  - Department of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 
      400, 69120, Heidelberg, Germany.
AD  - Medical Faculty of Heidelberg University, Heidelberg, Germany.
FAU - Dao Trong, Philip
AU  - Dao Trong P
AD  - Department of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 
      400, 69120, Heidelberg, Germany.
AD  - Medical Faculty of Heidelberg University, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20240308
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
SB  - IM
MH  - Adult
MH  - Humans
MH  - Middle Aged
MH  - Aged
MH  - Prospective Studies
MH  - *Neurosurgery
MH  - Postoperative Complications/epidemiology/etiology
MH  - *Brain Neoplasms/surgery/complications
MH  - Postoperative Hemorrhage
MH  - *Glioma/complications
PMC - PMC10923735
OTO - NOTNLM
OT  - Adverse events
OT  - Intracranial tumors
OT  - Morbidity
OT  - Tumor surgery
COIS- The authors declare no competing interests.
EDAT- 2024/03/08 12:42
MHDA- 2024/03/11 06:43
PMCR- 2024/03/08
CRDT- 2024/03/08 11:11
PHST- 2024/01/26 00:00 [received]
PHST- 2024/02/19 00:00 [accepted]
PHST- 2024/03/11 06:43 [medline]
PHST- 2024/03/08 12:42 [pubmed]
PHST- 2024/03/08 11:11 [entrez]
PHST- 2024/03/08 00:00 [pmc-release]
AID - 10.1007/s00701-024-06008-y [pii]
AID - 6008 [pii]
AID - 10.1007/s00701-024-06008-y [doi]
PST - epublish
SO  - Acta Neurochir (Wien). 2024 Mar 8;166(1):126. doi: 10.1007/s00701-024-06008-y.